Results 151 to 160 of about 4,766 (189)
Some of the next articles are maybe not open access.
Elvitegravir: An Emerging HIV Integrase Inhibitor
Future HIV Therapy, 2008Integration of the reverse transcribed HIV dsDNA into the host cell chromosome is critical for the subsequent production of progeny virions. In October 2007, the US FDA approved the first HIV-1 integrase inhibitor, raltegravir, as a therapeutic agent for treatment-experienced HIV-1-infected patients.
Kazuya Shimura, Eiichi Kodama
openaire +1 more source
Population Pharmacokinetics of Boosted‐Elvitegravir in HIV‐Infected Patients
The Journal of Clinical Pharmacology, 2015AbstractElvitegravir (EVG) is an HIV strand transfer integrase inhibitor approved for the treatment of HIV infection as a part of antiretroviral regimens containing cobicistat (COBI) or ritonavir (RTV) as a booster. The population pharmacokinetics of EVG in treatment‐naive and ‐experienced HIV patients was determined, and the effects of demographic ...
Joseph M, Custodio +4 more
openaire +2 more sources
Formulation and evaluation elvitegravir loaded microspheres
International Journal of Clinical Pharmacokinetics and Medical SciencesElvitegravir microspheres have been prepared and evaluated utilising the emulsion solvent diffusion technique as the study's goal. Elvitegravir was made using the emulsion solvent diffusion process and is filled with HPMC and ethyl cellulose microspheres.
{\\"name\\":\\"T Sreeja\\",\\"email\\":\\"sreejasridhar911@gmail.com\\",\\"affiliation\\":\\" +3 more
openaire +1 more source
Elvitegravir/cobicistat, mirabegron, and linaclotide
Journal of the American Pharmacists Association, 2012Daniel A, Hussar, Loren N, Martinez
openaire +2 more sources
Elvitegravir: a once daily alternative to raltegravir
The Lancet Infectious Diseases, 2012Desimmie, Belete Ayele +2 more
openaire +2 more sources